CellsBin® Scout™
CellsBin® Scout™
Reveal the Biology of Rare Therapeutic Cells in Blood
Scout delivers longitudinal single-cell insights with unmatched sensitivity, preserved phenotype, and decision-grade visibility for rare therapeutic cells in blood.
The observational gap
Scout Closes the Observational Gap in Cell and Gene Therapy
As therapeutic cells become rarer, conventional methods lose them. Scout keeps detecting — down to roughly one cell in a million, with phenotype preserved.
- Flow cytometry lacks the sensitivity to resolve rare populations.
- dd-PCR / NGS can count, but provides no phenotype insight.
- CB-Scout™ makes rare cells detectable, quantifiable, and phenotypically interpretable at one-in-a-million sensitivity or better.
Phenotypic depth
Reveal Surface and Intracellular Phenotypes at Single-Cell Level
Scout™ preserves phenotypic depth at the single-cell level, enabling drug developers and clinicians to profile both surface and intracellular markers from rare therapeutic cells in blood. This adds functional insight beyond simple detection and helps characterize state, identity, and biology over time.
Applications
One Observational Layer Across Cell Therapy Modalities
Scout supports diverse therapeutic formats with rich, single-cell phenotypic readouts — whatever the engineering approach, source, or delivery.
Engineered Immune Cell Therapies
- CAR-T Cell Therapy
- TCR-T Cell Therapy
- CAR-Treg
- CAR-NK / NK Cell Therapy
- FasT Cell Therapy
Adoptive Cell Therapies (ACT)
- TIL Therapy
- Donor Lymphocyte Infusion (DLI)
- Tumor-Targeted Lymphocytes
Stem, Regenerative & Platelet Therapies
- HSC / HSCT
- Mesenchymal Stem Cell (MSC) Therapy
- Progenitor Cell Therapy
- Platelet-Based Therapies
In Vivo & Smart Cell Therapies
- In Vivo CAR-T
- In Vivo Gene-Edited HSC
- Smart Cell Therapies
- M Cell Therapies
Workflow
From Samples to Answers
A simple, end-to-end experience for insights from rare therapeutic cells.
- 01
Panel selection
Select cell-surface and intracellular markers — a customizable panel tailored to your program.
- 02
Sample collection & shipping
Collect your sample — blood, PBMC, CSF, or other specimen types — and ship to CellsBin.
- 03
Scout reporting
CellsBin processes samples and delivers standardized, decision-ready Scout reporting.
Decision-grade packages
Across the Development Journey
One integrated approach to de-risk cell-therapy programs from IND readiness through long-term follow-up.
- 01
Preclinical / IND-Enabling
Mechanism-of-action evidence designed to support 21 CFR 312.20(a)(8) requirements and strengthen IND readiness.
- 02
FIH Dosing / Dose Escalation
In vivo pharmacokinetic evidence that complements safety data and supports first-in-human dosing decisions.
- 03
Phase I/II Translation
Translational evidence linking pharmacokinetics to patient response, persistence, and emerging toxicity signals.
- 04
Long-Term Monitoring
Longitudinal monitoring correlating pharmacokinetics with durability of response and late-onset adverse effects.
Start With a Pilot.
A low-friction entry point for biopharma teams seeking feasibility, longitudinal monitoring, or early clinical support.
- 01
Design the pilot
Define endpoints, markers, sample plan, and monitoring window.
- 02
Run samples
Generate standardized reports with decision-ready outputs.
- 03
Scale the program
Extend into IND-enabling studies or early clinical monitoring.